Streetbeat News

Price Targets

CTKB

Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on Cytek Biosciences (NASDAQ:CTKB) but lowered the price target from $8 to $7.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:02 pm

COTY

Morgan Stanley analyst Dara Mohsenian has maintained an Equal-Weight rating on Coty (NYSE:COTY) and lowered the price target from $13 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:59 pm

CHH

Morgan Stanley analyst Stephen Grambling maintains an Equal-Weight rating on Choice Hotels Intl (NYSE:CHH) and lowers the price target from $139 to $128.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:58 pm

ASND

Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $113 to $116.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:57 pm

APP

Morgan Stanley analyst Matthew Cost maintains an Equal-Weight rating on AppLovin (NASDAQ:APP) and raises the price target from $40 to $43.5.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:56 pm

WOW

Raymond James analyst Frank Louthan has maintained an Outperform rating on WideOpenWest (NYSE:WOW) but lowered the price target from $14 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:56 pm

FOLD

Morgan Stanley analyst Andrew Galler has maintained an Equal-Weight rating on Amicus Therapeutics (NASDAQ:FOLD) and raised the price target from $14 to $15.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:54 pm

PUBM

Raymond James analyst Andrew Marok has maintained an 'Outperform' rating on PubMatic (NASDAQ:PUBM), but lowered the price target from $18 to $17.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:54 pm

AIG

Morgan Stanley analyst Michael Phillips has maintained an Equal-Weight rating on American International Group (AIG) and raised the price target from $65 to $67.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:52 pm

RBLX

Raymond James analyst Andrew Marok maintains a Strong Buy rating on Roblox (NYSE:RBLX) and raises the price target from $41 to $47.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:52 pm